Also, liver-specific targeting of Dhx15 silencing and the generation of a conditional knockout to restrict the Dhx15 deficiency to the liver are needed to ensure the safety of an anti-Dhx15 therapeutic strategy in the context of tumor treatment and to prevent side effects in other organs. Here, DHX15 is linked to neoplasm.